Seoul National University Bundang Hospital

HIMSS today announced an update to its Adoption Model for Analytics Maturity at the HIMSS24 Asia-Pacific conference in Seoul. The earlier version of AMAM will now be referred to as AMAM Classic and the modernised version will be referred to as AMAM24. WHY IT MATTERS The new AMAM maturity framework centres on five key imperatives for healthcare organisations: Governance; Analytics life cycle; Data and infrastructure; Personalised analytics; and Analytics impact and outcomes. HIMSS redesigned the AMAM to enable the successful adoption of advanced analytics, and AI in particular, for health organisations to achieve priority outcomes. It begins with the foundational requirements of data, digital infrastructure, and governance. Like the other HIMSS maturity models, AMAM24 is structured around a ladder of eight maturity stages - from zero to seven - to help healthcare organisations optimise their healthcare analytics capabilities, offering an evidence-based framework for improving data governance, predictive analytics, and AI usage. THE LARGER TREND Globally, 26 organisations achieved Stage 6 and 13 have achieved Stage 7 for the AMAM. In APAC, two organisations ( China Medical University Hospital , and Seoul National University Bundang Hospital) have reached AMAM Stage 6. South Korea's Samsung Medical Centre is the only organisation in APAC to have achieved Stage 7 . ON THE RECORD "AMAM24 does not prescribe what policy framework should be used in an organisation; however, it does require evidence of analytics strategy and governance policies which support and enable safety and quality of care," said Widi Salim, Senior Digital Health Advisor, HIMSS. "AMAM24 expands its earlier focus on data and IT to also now include prescriptive analytics, and data driven decision making."

TUESDAY, Sept. 3, 2024 -- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors may prevent dementia in middle-aged adults with diabetes, according to a study published online Aug. 28 in The BMJ . Anna Shin, from Seoul National University Bundang Hospital in South Korea, and colleagues compared the risk for dementia associated with SGLT-2 inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors in adults (aged 40 to 69 years) with type 2 diabetes. The analysis included 110,885 propensity-matched pairs followed for a mean of 670 days. The researchers found that the incidence rate for dementia was 0.22 per 100 person-years in initiators of SGLT-2 inhibitors and 0.35 per 100 person-years in initiators of DPP-4 inhibitors (hazard ratios: 0.65 for dementia, 0.54 for dementia requiring drugs, 0.61 for Alzheimer disease, and 0.48 for vascular dementia). Findings persisted regardless of dementia type and across subgroups categorized by age, sex, concomitant use of metformin, and baseline cardiovascular risk. When adjusting for residual confounding (measured by cataract surgery), the risk for dementia remained lower (hazard ratio, 0.70). The association was stronger for treatment of more than two years (hazard ratio, 0.57). "Highly consistent results over a range of secondary and sensitivity analyses supported the robustness of our study findings," the authors write. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

All 43 public hospitals under Hong Kong Hospital Authority have been validated for Stage 7 of the HIMSS Electronic Medical Record Adoption Model . The EMRAM is a globally validated model that measures an organisation's maturity in the use of EMR technology. WHY IT MATTERS After achieving Stage 6 of the EMRAM, HA set its sights on getting validated for the highest EMRAM stage in line with its smart hospital transformation strategy. "The HA had previous experience achieving Stage 6 validation, but Stage 7 represented a significant step up in the level of requirements and scrutiny," admitted Dr Ngai Tseung Cheung, head of Information Technology and Health Informatics at HA. Working with the HIMSS team, HA developed a comprehensive project plan for this endeavour. "The preparation phase was intensive, with hundreds of meetings and regular checkpoint sessions with HIMSS. This allowed us to refine our approach and ensure we were addressing all the necessary criteria," said Dr Cheung. The plan, HA shared, involved mobilising clinical and business leaders across all its hospitals, which was crucial in ensuring alignment from all key stakeholders. As advised by HIMSS, it also had to scale back some initiatives, such as AI projects, so it could double down on meeting specific requirements for the Stage 7 validation. One of those key projects was the upgrade of the clinical management system (CMS), which has been in operation since 1994. Used by over 70,000 staff, the system handles about 43 million transactions daily. HA's fourth-generation CMS, integrated across all 43 public hospitals, 74 general outpatient clinics, and 49 specialist clinics, features paperless operations, clinical procedure support, and closed-loop clinical management. It has several clinical modules, including: IPMOE , a closed-loop computerised system for prescribing, dispensing, and administering drugs for inpatients; the Result Screening app which facilitates investigation reports screening and follow-up; e-Vital , which supports accurate data capture; the digital assistant e-Scribe for automating clinical workflow; and the Smart ASP which uses data analytics to monitor prescriptions and evaluate antibiotic use, etc. The mobile patient app HA Go is another key project. The smartphone app integrates various health services, including appointment scheduling, medication management, and telehealth consultations. During the EMRAM assessment, HIMSS validators commended HA for actively promoting patients' uptake of this app. HA Go has over five million registered users since its launch in 2019 . Following the assessment, HA plans to further enhance the clinical capabilities of its CMS and expand the features of the HA Go app. "Efforts will be directed towards developing and supporting initiatives for smart hospitals, improving patient and staff experiences through more efficient and effective workflows, leveraging automation and integration technologies for clinical care, hospital support, and management processes," Dr Cheung mentioned. Over the past two years, HA has deployed dozens of smart hospital solutions across its network. These include a product suite consisting of smart bed panels, electronic vital capture, smart kiosks, and integration to HA Go has helped reduce wait times and facilitated smoother hospital workflows. AI and data analytics have also been implemented to enhance disease diagnosis accuracy and safety, including AI-assisted radiology diagnostics and clinical prediction. THE LARGER TREND Early this year, Princ Hospital Suvarnabhumi in Thailand was also validated for Stage 7 of the HIMSS EMRAM. In addition, Seoul National University Bundang Hospital in South Korea and Chang Gung Memorial Hospital-Linkou in Taiwan were revalidated for this stage over the past 12 months. ON THE RECORD "HA's successful EMRAM validation is a significant milestone that underscores the remarkable progress in our digital transformation journey over the past decades. Achieving the Stage 7 EMRAM recognition from HIMSS validates HA's continuous efforts to prioritise patient-centred care and operational efficiency at the highest level. This milestone reflects the unwavering support and collaboration of all HA healthcare professionals and staff, who have worked tirelessly to drive excellence and maintain the highest standards in healthcare IT to meet the unique needs of the Hong Kong population," said Dr Cheung.